Skip to main content
Pangen Biotech Inc. logo

Pangen Biotech Inc. — Investor Relations & Filings

Ticker · 222110 ISIN · KR7222110009 KO Manufacturing
Open in API
Filings indexed 333 across all filing types
Latest filing 2021-03-29 Declaration of Voting R…
Country KR South Korea
Listing KO 222110

About Pangen Biotech Inc.

https://pangen.com/layout/eng/home.php

Pangen Biotech Inc. is a biotechnology company specializing in the research, development, and manufacturing of biopharmaceuticals. The company utilizes its proprietary platform technologies, particularly those based on Chinese Hamster Ovary (CHO) cell lines, for the production of complex protein therapeutics. Its primary business activities include the development of a pipeline of biosimilar products, such as Erythropoietin (EPO) and Aflibercept. In addition to its own product pipeline, Pangen Biotech offers Contract Development and Manufacturing Organization (CDMO) services, providing expertise in cell line development and biopharmaceutical production to other firms. The company also supplies reagents and kits for research applications.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed, including financial statement approval, dividend decisions, and board/auditor compensation limits. Since it reports the official outcomes of the shareholder votes at the Annual General Meeting, it falls under the 'Declaration of Voting Results & Voting Rights Announcements' category.
2021-03-29 Korean
사업보고서 (2020.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Business Report' (사업보고서) for the fiscal year 2020, covering company overview, management, capital structure, and detailed business operations. It contains financial data and management analysis, which aligns with the definition of an Annual Report (10-K). FY 2020
2021-03-19 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Pangen Inc. It contains the meeting agenda, including the approval of financial statements, changes to the articles of incorporation, and director/auditor compensation limits. It also includes detailed management information regarding business operations, market status, and R&D activities, which is typical for the 'Management Reports' (MDA) section of a proxy statement or a comprehensive shareholder meeting notice in the Korean regulatory context. Since it provides detailed management's explanation of business trends and outlook alongside the meeting notice, it is classified as a Management Report.
2021-03-12 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company Pangen. It outlines the date, time, location, and the agenda items (such as financial statement approval, articles of incorporation changes, and director compensation limits) to be voted upon. This document serves as the official proxy solicitation and meeting notice provided to shareholders, which falls under the Proxy Solicitation & Information Statement category.
2021-03-11 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the personal share transactions (disposal of shares) by an executive (Kim Ji-tae) of the company Pangen. This type of filing is a standard regulatory requirement for insider trading/director dealings in South Korea, which corresponds to the 'Director's Dealing' category.
2021-03-03 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a short regulatory filing from a Korean company (Pangen) announcing the submission of its audit report. It provides a summary table of financial data (assets, liabilities, profit/loss) and audit opinions, which is standard for a 'Report Publication Announcement' (RPA) in the Korean market (DART system). It is not the full audit report itself, but rather the official notification that the audit report has been submitted to the regulator. FY 2020
2021-03-03 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.